Name: BioNexus Gene Lab Corp. (BGLC) Financial Statements
Creator: FinSpry

BioNexus Gene Lab Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

BioNexus Gene Lab Corp. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	9.51	9.77	10.93	13.36	11.39
Cost of Revenue	8.22	8.44	9.67	11.10	9.67
Gross Profit	1.29	1.33	1.26	2.27	1.72
Operating Expenses
Research & Development	0.05	0.05	0.00	0.00	0.00
Selling, General & Administrative	4.00	3.04	1.73	1.28	1.33
Operating Expenses	3.19	4.37	1.55	1.21	1.15
Operating Income	-1.90	-3.04	-0.29	1.06	0.57
Other Income/Expense
Interest Income	0.22	0.13	0.00	0.00	0.00
Interest Expense	-0.02	-0.01	0.01	0.01	-0.01
Other Income/Expense	0.24	0.42	0.00	0.00	0.00
Income
Income Before Tax	-1.59	-2.61	-0.30	1.04	1.26
Income Tax Expense	0.00	0.02	0.05	0.29	0.17
Net Income	-1.60	-2.63	-0.36	0.75	1.09
Net Income - Continuous Operations	-1.60	-2.63	-0.36	0.75	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-1.79	-2.95	-0.19	1.16	0.66
EBIT	-1.90	-3.04	-0.29	1.06	0.57
Depreciation & Amortization	0.10	0.08	0.11	0.11	0.09
Earnings Per Share
Basic EPS	-1.00	-2.00	-	-	1.00
Diluted EPS	-1.00	-2.00	-	-	1.00
Basic Shares Outstanding	1.78	1.59	1.44	1.43	0.86
Diluted Shares Outstanding	1.78	1.59	1.44	1.43	0.86